EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evidence of decreased plasma substance p levels in human essential hypertension influence of prazosin treatment


, : Evidence of decreased plasma substance p levels in human essential hypertension influence of prazosin treatment. Biomedica Biochimica Acta 42(7-8): 1019-1026

Patients with essential hypertension (n = 45) had significantly lower substance P plasma levels (13.6 .+-. 2.30 pg/ml) in comparison with a group of 24 normotensive subjects (45.4 .+-. 7.18 pg/ml) analyzed by radioimmunoassay. Prazosin treatment for 2 wk with 4.5 mg/day enhanced the substance P plasma level depending on its antihypertensive effect. Norepinephrine concentration in plasma was also elevated by prazosin. Dipeptidylpeptidase IV, dopamine-.beta.-hydroxylase and plasma renin activity were not changed significantly. Evidently, substance P participates in pathophysiological processes of human essential hypertension.


Accession: 005411339

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Faulhaber, H.D.; Rathsack, R.; Rostock, G.; Homuth, V.; Pfeiffer, D.; Naumann, E.; Hartrodt, W.; Görne, R.C.; Oehme, P., 1983: Evidence of decreased plasma substance P levels in human essential hypertension and influence of prazosin treatment. Patients with essential hypertension (n = 45) had significantly lower substance P plasma levels (13.6 +/- 2.30 pg/ml) in comparison with a group of 24 normotensive subjects (45.4 +/- 7.18 pg/ml) analyzed by radioimmunoassay. Prazosin treatment for...

Anonymous, 1977: Open studies with prazosin in the treatment of essential hypertension. Prazosin Research Group in Japan. The clinical usefulness of prazosin was investigated in 67 patients with mild to moderate essential hypertension for 6 to 12 weeks. The daily doses were increased from 3 to 9 mg according to the responses of the patients. The average reduction of...

Falch D.K.; Paulsen A.Q.; Odegaard A.E.; Norman N., 1979: Central and renal circulation renin and aldo sterone in plasma during prazosin treatment in essential hypertension. The hemodynamic adaptation and the change in the renin-aldosterone system during treatment with a new vasodilating drug, prazosin (Peripress), were studied in 14 patients with essential hypertension before and after 2 and 4 mo. of treatment. The m...

Osotimehin, B.; Lawal, S.O.; Iyun, A.O.; Falase, A.O.; Pernollet, M.G.; Devynck, M.A.; Meyer, P., 1988: Plasma levels of digitalis-like substance in Nigerians with essential hypertension. A plasma Na+-K+ ATPase inhibitor, which is estimated by a technique in which it competes with ouabain for binding on red cells, was measured in three groups of individuals: (a) normotensive subjects without a family history of hypertension, (b) no...

Geroldi, D.; Falcone, C.; Emanuele, E.; D'Angelo, A.; Calcagnino, M.; Buzzi, M.P.; Scioli, G.A.; Fogari, R., 2005: Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. Objectives Advanced glycation end-products (AGE) may cause vascular stiffening by forming crosslinks through the collagen molecule or by interaction with their cellular transductional receptor (RAGE). A secreted isoform of RAGE, termed soluble RAG...

Wiecek, A.; Kokot, F.; Zukowska-Szczechowska, E., 1993: The effect of long-term prazosin treatment on plasma follitropin (FSH), lutropin (LH), prolactin, estradiol and testosterone concentration in male patients with essential hypertension. The influence of prazosin treatment for 12 months on basal and LH-RH stimulated FSH, LH, estradiol and testosterone secretion and basal and chlorpromazine stimulated prolactin secretion was estimated in 15 male patients with essential hypertension...

Blacher, J.; Amah, G.; Girerd, X.; Kheder, A.; Ben Mais, H.; London, G.M.; Safar, M.E., 1997: Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. We previously observed that, in subjects with essential hypertension, acute ouabain constricts th brachial artery diameter in the presence of spironolactone treatment, a finding that is not observed in the absence of aldosterone antagonist and the...

Blacher, J.; Amah, G.; Girerd, X.; Kheder, A.; Ben Mais, H.; London, G.M.; Safar, M.E., 1998: Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. We previously observed that, in subjects with essential hypertension, acute ouabain constricts the brachial artery diameter in the presence of spironolactone treatment, a finding that is not observed in the absence of aldosterone antagonist and th...

Falch D.K.; Odegaard A.E.; Norman N., 1979: Decreased renal plasma flow during propranolol treatment in essential hypertension. The pharmacodynamic effect of propranolol (80 mg bid [twice daily]) on the renal and systemic circulation was studied after 1 and 8 mo. of treatment in 13 patients with essential hypertension, using non-invasive radioisotope techniques. Effective...

Elliott, H.L.; Meredith, P.A.; Reid, J.L., 1987: Verapamil and prazosin in essential hypertension: evidence of a synergistic combination?. An enhanced hypotensive effect has been observed in short-term studies of the combination of an alpha-adrenoceptor antagonist and a calcium channel blocker. This study further evaluates combined treatment with prazosin and verapamil in 12 essentia...